A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

NCT02418819 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: PF-06412562 3mg BID
DRUG: PF-06412562 9mg BID
DRUG: PF-06412562 45mg BID
OTHER: Placebo

Sponsor

Pfizer